Key Takeaways
- Valuation gaps between private buyers and DSOs can reach 40–80% for practices above $1–1.5 million in collections, driven by EBITDA multiples versus revenue-based pricing.
- Normalized EBITDA, after proper add-backs for owner compensation and discretionary expenses, directly lifts the final sale price when a competitive process is used.
- Structured competitive sell-side processes typically deliver 50% higher transaction values than accepting the first unsolicited DSO offer.
- Deal structure matters, because most DSO offers split value into cash at close, rollover equity, and earnouts, so headline multiples rarely equal cash received on closing day.
- McLerran & Associates provides side-by-side valuations and runs competitive bid processes to help owners maximize outcomes. Schedule a free, confidential discovery call to learn what your practice may be worth today.
Two Valuation Playbooks: Private Buyers vs. DSOs
Dental practice valuation in 2026 follows two main playbooks, and the gap between them can be substantial for qualifying practices.
Individual dentist buyers using conventional or SBA financing typically value practices as a percentage of annual collections, or as a multiple of seller’s discretionary earnings (SDE, meaning the practice’s net income before the owner’s compensation and certain other adjustments). General dental practices in private, doctor-to-doctor transactions tend to trade at roughly 65–85% of annual collections, a range constrained by what a bank will lend after the new owner takes a salary and services the debt.
Dental service organizations and private equity-backed platforms use EBITDA instead. EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization, and it measures operating profitability after normalizing out owner-specific expenses. Because institutional buyers apply a multiple to this profitability figure rather than to gross revenue, and because they often have access to cheaper capital than individual dentists, a practice generating $2 million in annual revenue with $400,000 in EBITDA might transact at $1.3–1.7 million to a private buyer versus $2.4–2.8 million to a dental service organization buyer, which creates a 40–80% valuation gap on identical fundamentals.
This gap does not apply to every practice. It tends to apply most strongly to practices above roughly $1–1.5 million in annual collections, where dental service organization interest becomes serious and competitive. Below that threshold, private-buyer and institutional valuations can converge, and a doctor-to-doctor sale may be the more efficient path.
EBITDA Multiples: Where Practices Typically Land
For practices where the DSO path makes sense, the next question usually focuses on the EBITDA multiple the practice may receive. Multiples depend on several interconnected factors, because they reflect the full picture of earnings quality, transferability, and the competitive dynamics of the sale process.
Current market data can provide useful directional context. In 2026, dental practices broadly sell for 5–11x adjusted EBITDA, with the range shaped by practice size, provider structure, payer mix, and whether the sale runs as a competitive process or a single-buyer negotiation. Solo general practices tend to cluster at the lower end of the range, while multi-location groups and platform-scale practices with strong EBITDA can reach the upper end.
Specialty practices, including oral surgery, orthodontics, and pediatric dentistry, can command a meaningful premium over general dentistry in dental service organization transactions, reflecting higher margins and more durable, referral-driven revenue. However, the specific premium varies significantly by specialty, market, and buyer, which is why each practice should be evaluated individually rather than relying on general assumptions.
The factors that can move a practice toward the upper end of its applicable range include:
- Low owner dependence. Practices where the selling doctor produces 90% or more of clinical revenue can face effective valuation discounts of 25–40% compared to practices with distributed associate production, because buyers hesitate to underwrite revenue that may leave at closing.
- Strong hygiene production. Strong hygiene production often supports higher valuations, because it reflects recurring, predictable cash flow that buyers can underwrite with more confidence.
- Favorable payer mix. A high fee-for-service or commercial PPO mix can support higher multiples than PPO-heavy practices, while high Medicaid concentration can compress multiples.
- Growth trajectory and operational systems. Practices demonstrating consistent annual collections growth, overhead below 65% of collections, and documented operational systems often command higher multiples from institutional buyers.
- Modern technology and clean reporting. Digital radiography, intraoral scanning, and cloud-based practice management systems can reduce post-acquisition integration risk for dental service organization buyers and support stronger valuations.
Normalized EBITDA: Add-Backs That Move the Needle
Normalized EBITDA sits at the center of DSO valuation, because buyers pay a multiple of this number. Normalization adjusts EBITDA to reflect true, transferable operating profitability rather than the owner’s personal financial decisions, and a careful process can materially increase what a buyer is willing to pay.
Common add-backs in dental practice EBITDA normalization can include:
- Owner compensation reset. The owner-doctor’s compensation is replaced with a market-rate clinical salary, which creates an upward EBITDA adjustment that can range from $100,000 to $400,000 per owner.
- Personal and discretionary expenses. Personal and discretionary expenses, such as certain vehicle expenses, family payroll, and non-business travel, can be added back when removed from the profit and loss statement with documentation.
- One-time and non-recurring costs. Items such as legal settlements, practice management software transitions, and COVID-era expenses are often normalized out of base-year EBITDA on a case-by-case basis.
- Above- or below-market rent adjustments. Owner-occupied building rent that differs from arm’s-length market rates usually requires an EBITDA adjustment, with real estate typically negotiated separately from practice enterprise value.
Thorough normalization can significantly increase a practice’s reported EBITDA and, at the applicable multiple, can create a meaningful valuation impact. At higher multiples, the effect compounds further. A weak or incomplete normalization analysis, by contrast, can set a low anchor that buyers may use throughout diligence.
This dynamic explains why McLerran & Associates builds a CPA-led, diligence-grade EBITDA analysis before any practice goes to market. The goal is a number that holds up when buyers look under the hood, not one that gets re-traded after an LOI (letter of intent, the formal offer document that precedes a purchase agreement) is signed.
Sale Process and Competitive Bidding
Even with a strong EBITDA foundation in place, the multiple a practice receives is not determined solely by its fundamentals. The sale process itself can be equally consequential, and the data on this point remains consistent across multiple sources.
Practices sold through structured competitive processes typically achieve final transaction values 50% above initial offers. This premium reflects straightforward competitive dynamics, because multiple qualified buyers must put their best offer forward instead of anchoring to a single low number.
Off-market dental practice acquisitions tend to trade at approximately 50% lower values than those achieved through competitive marketed processes. A dentist who accepts the first unsolicited dental service organization offer, without understanding what the broader market may pay, effectively negotiates against themselves.
The spread between an unsolicited offer and the final negotiated deal in a competitive process has averaged 50% in total transaction value for U.S. dental practices. On a practice with a $5 million EBITDA at a 7x multiple, this premium can represent millions of dollars in additional realized value.
McLerran & Associates runs a structured, auction-style bid process over roughly 45–60 days among a vetted pool of well-qualified buyers, typically generating around 10 offers per listing. That competitive tension serves as the mechanism that produces stronger pricing and terms.
Deal Structure: From Headline Price to Cash at Close
Deal structure often determines how much value a seller actually realizes at closing. A dental service organization offer usually includes several components rather than a single number.
Most institutional transactions combine cash at close with rollover equity, which is a retained ownership stake in the acquiring platform, and an earnout, which is a contingent payment tied to post-close performance targets. A typical dental service organization transaction structure allocates roughly 60–75% of total value as cash at close, 15–30% as rollover equity, and 5–15% as earnout.
This structure means the headline multiple and the cash a seller receives on closing day can differ in a meaningful way. A buyer may quote a 7x multiple, but the economics change if diligence reduces EBITDA, debt-like items are identified, or value is pushed into rollover equity or contingent consideration. To calculate what the seller may actually receive, it helps to work through this formula: Enterprise Value minus net debt, plus or minus working capital adjustments, minus escrow, earnouts, rollover equity, and holdbacks. The amount that remains represents estimated cash at close.
Rollover equity deserves particular attention. As a retained stake in the dental service organization platform, it carries both upside potential, often described as a second bite of the apple if the platform recapitalizes at a higher multiple, and downside risk if the dental service organization underperforms. The equity portion of a dental service organization deal typically monetizes only at a second exit in 5–7 years, which means a meaningful share of the seller’s proceeds may remain illiquid for an extended period.
Earnouts introduce a different kind of risk. Associate doctor retention post-close is one of the most common reasons dental service organization earnouts are clawed back or fail to pay out. Negotiating non-punitive earnout terms, such as pro-rata provisions, later start dates, and metrics the seller can realistically influence, can be a material part of protecting the deal’s realized value.
McLerran & Associates prepares multi-year, multi-structure financial forecasts for every dental service organization engagement. These models estimate what each offer may net the owner over 3, 5, 7, and 10 years, including conservative recapitalization assumptions, so clients can compare options on a true after-tax, after-structure basis rather than relying on a headline number.
Choosing Between a Private Buyer and a DSO
The right transition path usually depends on the practice’s size, the owner’s goals, and local market dynamics. Neither path fits every situation.
For practices in roughly the $1–1.5 million revenue range, a doctor-to-doctor sale can often be the most efficient path. This route can deliver a clean exit, a simpler deal structure, and a buyer who may preserve the practice’s legacy and patient relationships. Private buyer transactions typically deliver 100% of the agreed purchase price at closing with no performance contingencies, and the transition period is often measured in weeks rather than years.
For practices above roughly $1.5 million in annual revenue, particularly those with associate production, strong EBITDA margins, and growth capacity, the DSO path can deliver materially higher total proceeds, even after accounting for the complexity of deal structure. DSO transactions can provide a premium over private-buyer offers where strategic platform fit is strong.
For practices in the $1.5–3 million revenue range, both paths may be genuinely viable. The most informed answer usually comes from a side-by-side valuation that quantifies the practice’s worth in both markets. Because McLerran & Associates works both paths in roughly equal measure, the firm can produce that comparison with real data rather than a guess.
Timing Your Transition and Preparing the Practice
Owners who achieve top-quartile prices typically begin preparing their practices 24–36 months before speaking with any buyer. That runway allows time for operational improvements, such as reducing owner dependence, strengthening hygiene production, and cleaning up financials, to appear in the trailing financial statements that buyers evaluate. Improvements implemented in the final months before a sale are often discounted by buyers as transaction-motivated.
A typical dental practice sale takes 6 to 12 months from engagement to close, with DSO deals running 3 to 6 months of active process and individual-buyer sales closing in 60 to 120 days. In either case, the process usually feels longer and more complex than most owners expect, and the quality of preparation going in can shape the outcome at every stage.
Owners who are not ready to sell today can still benefit from an early conversation. McLerran & Associates will update a practice valuation for free a year after the initial analysis, so owners can track where they stand and make informed decisions about timing without pressure.
FAQ
How does McLerran & Associates determine what my practice is worth?
McLerran & Associates builds a comprehensive, CPA-led EBITDA analysis for every engagement by remotely accessing your practice management software, pulling the relevant reports, and cross-referencing the data against your financials. The team unpacks every discretionary, personal, and non-recurring expense to arrive at true, normalized profitability. For doctor-to-doctor deals, value is calculated as a percentage of revenue or a multiple of net cash flow. For DSO and private equity deals, value is calculated as a multiple of EBITDA. If you are weighing both paths, the firm delivers a side-by-side valuation that quantifies your worth in both markets. This work is designed to be diligence-grade from the start so that it holds up when buyers scrutinize it and does not get re-traded after a letter of intent is signed.
What is the difference between a headline offer and what I actually receive at closing?
In a DSO transaction, the headline offer and the cash you receive at closing can differ significantly. Most institutional deals combine cash at close with rollover equity, which is a retained ownership stake in the acquiring platform, and an earnout, which is a contingent payment tied to post-close performance targets such as production levels or associate retention. The equity portion is typically illiquid for several years and depends on the DSO platform’s future performance. The earnout may or may not pay in full, depending on metrics that are sometimes outside the seller’s control. McLerran & Associates models what each offer may net you over multiple time horizons, including conservative assumptions about recapitalization, so you can compare options on a true after-tax, after-structure basis rather than relying on a headline number.
How do I know if a dental service organization is a good partner, not just a high bidder?
Vetting buyers forms a core part of McLerran & Associates’ work. The firm evaluates dental service organization buyers the way an investor might evaluate a stock. The analysis considers whether the company as a whole is profitable, whether revenue is still growing at the offices it already owns, whether the management team is experienced, and whether the private equity firm backing it has successfully completed this kind of transaction before. McLerran has blacklisted dental service organizations known for creating poor post-close environments, including undercapitalized buyers that emerged when capital flooded the space, so poorly run platforms never reach the table. The goal is to find a buyer whose strategy, structure, and support model align with what you want for your practice after you step back, not just the buyer willing to put the highest number on paper.
Does running a competitive process really make a meaningful difference to the final price?
The available data suggests that structured competitive processes can produce materially better outcomes than single-buyer negotiations. Practices sold through marketed processes with multiple buyer solicitation have averaged final transaction values 50% above initial unsolicited offers, with sellers typically receiving five or more offers. The mechanism remains straightforward, because multiple qualified buyers must put their best offer forward, and the seller negotiates from strength instead of from a single anchor. Beyond headline price, competition can also improve non-price terms, including earnout structure, equity mechanics, employment agreement duration and compensation, and legal protections. McLerran & Associates’ structured bid process typically generates around 10 offers per listing over a 45–60-day window, which creates the competitive tension that can improve both price and terms.
Should I sell to a private buyer or affiliate with a DSO?
The right answer usually depends on your practice’s size and profitability, your personal goals, and your timeline. Smaller premier practices, roughly in the $1–1.5 million revenue range, often fit a doctor-to-doctor sale, which can deliver a simpler structure, a cleaner exit, and a buyer focused on preserving your legacy. Larger practices, particularly those above $1.5 million in revenue with associate production and strong EBITDA, may achieve materially higher total proceeds through a DSO affiliation, although that path involves a more complex deal structure and a multi-year working commitment. Practices in the $1.5–3 million revenue range can often go either way, and the decision is usually best made with a side-by-side valuation that quantifies your worth in both markets. Because McLerran & Associates works both paths in roughly equal measure, the firm can produce that comparison with real data and help you choose the path that aligns with your goals rather than the path a single-lane broker happens to offer.
